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Abstract 
Background: To be able to develop effective therapeutics for epidermolysis bullosa simplex (EBS), it is necessary 
to elucidate the molecular pathomechanisms that give rise to the disease’s characteristic severe skin-blistering 
phenotype.
Results: Starting with a whole-transcriptome microarray analysis of an EBS Dowling-Meara model cell line (KEB7), 
we identified 207 genes showing differential expression relative to control keratinocytes. A complementary qRT-PCR 
study of 156 candidates confirmed 76.58 % of the selected genes to be significantly up-regulated or down-regulated 
(p-value <0.05) within biological replicates. Our hit list contains previously identified genes involved in epithelial cell 
proliferation, cell-substrate adhesion, and responses to diverse biological stimuli. In addition, we identified novel can-
didate genes and potential affected pathways not previously considered as relevant to EBS pathology.
Conclusions: Our results broaden our understanding of the molecular processes dysregulated in EBS.
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Background
KRT5 and KRT14 are the main stress-absorbing kerat-
ins in basal keratinocytes of the epidermis and related 
stratified epithelia. These rod-shaped proteins form het-
erodimeric units that interact to build up the cytoskel-
etal intermediate filament (IF) network, a resilient yet 
adaptable scaffold that maintains cellular structural sta-
bility and, in turn, normal skin integrity and function. 
Disruption of IF-organization as a consequence of kera-
tin mutation is the basis of a number of inherited skin 
fragility syndromes [1, 2]. In the case of epidermolysis 
bullosa simplex (EBS), which exhibits several clinical 
variants [3], specific phenotypes can be largely corre-
lated with the positions of missense mutations in struc-
turally sensitive portions of either KRT5 or KRT14 [4]. 
Aberrant IF organization results in fragile epidermal 
basal cells that readily lyse following mild mechanical 
trauma or minor traction, leading to intraepithelial fluid 
accumulation and recurrent blister formation [5–8]. At 
the molecular level, this cytoskeletal collapse manifests 
as aggregates of misfolded keratins, along with activa-
tion of stress-response cascades [9, 10]. Detailed eluci-
dation of the underlying pathomechanisms in EBS is an 
important prerequisite for developing innovative thera-
peutics; however, relatively few studies have focused on 
expression-profiling of mutant epidermal cells (summa-
rized in Additional file 1: Table S1). In 2007, Lu et al. [11] 
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reported the expression profile of KRT5−/− EBS mouse 
epidermis, concentrating mainly on the regulation of 
inflammatory cytokines. Liovic et  al. [12] investigated 
the response of the EBS keratinocyte cell lines KEB4 
(mild EBS-loc phenotype, KRT14 mutation V270  M) 
and KEB7 (severe EBS Dowling-Meara (EBS-DM) phe-
notype, K14 mutation R125P) to hypo-osmotic stress in 
comparison to the wild-type cell line NEB1, and found 
dual-specificity phosphatases and their downstream tar-
gets ERK and p38 to be differentially regulated in EBS 
cells. A subsequent study by the same group identified 
differences in the expression profiles of cell-junction 
components in EBS versus wild-type cell lines [13]. More 
recent profiling studies reported aberrant expression of 
genes involved in keratinization, cell growth, prolifera-
tion, the immune response, and fatty acid metabolism in 
EBS [14]. Because there is limited overlap of the genes 
identified in those studies, further efforts seem necessary 
to fully elucidate EBS-relevant genes to better under-
stand EBS pathology. We recently described the gene 
expression profile of KEB7 cells after applying suppres-
sion subtractive hybridization, and found dysregulated 
genes involved in keratinocyte differentiation, migration 
and wound healing [15]. Here, we follow-up that analysis 
with a more expansive expression profiling study, com-
bining whole-transcriptome microarray examination 
with bioinformatics-assisted functional clustering, com-
plementary qRT-PCR validation, and western blotting 
analysis of selected hits. Using this approach we were 
able to verify candidate genes previously described as 
being differentially expressed in EBS-DM, and to dis-
cover other differentially regulated genes not previously 
implicated in EBS pathology. A graphical summary of 
our experimental design is shown in Fig. 1.
Methods
Cell lines and culture conditions
The immortalized keratinocyte cell lines KEB7 (EBS-
DM severe phenotype caused by the R125P mutation in 
KRT14) and NEB1 (wild-type control cell line) [16] were 
cultured in standard DMEM (HyClone Laboratories, GE 
Healthcare, South Logan, UT, USA) supplemented with 
25 % Ham’s F12 nutrient mixture, 10 % fetal bovine serum 
(FBS), 1.8 × 10−4 M adenine, 0.4 µg/ml hydrocortisone, 
5  µg/ml transferrin, 2 ×  10−11 M liothyronine, 5  µg/ml 
insulin and 10  µg/ml EGF. Unless otherwise stated, all 
chemicals and reagents were obtained from Life Tech-
nologies™ (Karlsruhe, Germany) or Sigma-Aldrich Inc. 
(Taufkirchen, Germany). Cell lines were cultivated in 
standard 25  cm2 flasks (Techno Plastic Products AG, 
Trasadingen, Switzerland) at 37  °C under a 5  % CO2 
atmosphere without fibroblast feeder cells.
Fig. 1 Experimental design of our study
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Total RNA isolation from cultivated KEB7 and NEB1 cells
Total RNA from cells grown to approximately 80  % 
confluence was isolated using an RNeasy Mini Kit 
(QiagenGmbH, Hilden, Germany) according to the man-
ufacturer’s instructions. RNA was resuspended in nucle-
ase-free water and quantified spectrophotometrically 
at 260  nm (DS-11 Spectrophotometer, DeNovix, Wilm-
ington, DE, USA). RNA preparations were considered as 
suitable only if samples were of sufficient yield, exhibited 
intact bands on agarose gels, and displayed no spurious 
peaks or RNA degradation artifacts on the UV absorp-
tion spectrum. RNA samples were stored in aliquots at 
−80 °C.
Whole‑transcriptome microarray analysis
Total RNA, isolated from a pool of different passages of 
KEB7 versus NEB1 cells (p25 and p28–37), was used for 
probing a high-precision, whole-transcript Human Gene 
1.0 ST array (Affymetrix, Santa Clara, CA, USA). The 
entire experimental pipeline, from sense target labeling 
to hybridization, washing, array scanning and final raw 
data capture, was performed at the Center of Excellence 
for Fluorescent Bioanalysis KFB, University of Regens-
burg, Germany, using standard Affymetrix protocols, 
reagents and instrumentation. Four microarrays per cell 
line were processed to account for technical and/or bio-
logical variability. The raw data were checked for quality, 
background-adjusted, quantile-normalized (by impos-
ing the same distribution of gene signal intensities for 
each array used under the condition that the expression 
of most genes is relatively unaltered across mutant and 
wild-type cells), and statistically analyzed by the linear 
model for microarray data (LIMMA) method [17] using 
the Integromics Biomarker Discovery® platform (IBD, 
Integromics, Granada, Spain). Assuming experimen-
tal deviations/errors of less than a log2-fold change of 
+1/−1, only candidates showing regulation greater than 
+2/−2 were subjected to further analysis. The respective 
statistical parameters were also used for the subsequent 
enrichment and qRT-PCR studies.
Gene ontology enrichment and functional clustering 
of differentially expressed genes
Affymetrix IDs of differentially regulated genes were 
subjected to comprehensive bioinformatical analysis 
embedded within IBD. Gene ontology (GO) classifica-
tion was performed to confirm enrichment of micro-
array-derived genes and to assign them to specific 
biological themes and functions. To ascertain GO-term 
enrichment of genes statistically overrepresented in the 
candidate hit list (log2-fold change of ≥ +1 and ≤ −1, 
adjusted p-value of  <0.05), the software tool calculated 
a one-sided hypergeometric p-value (identical to the 
one-tailed version of Fisher’s exact test), so that terms 
with values below 0.05 can be considered to be signifi-
cantly enriched.
cDNA synthesis, primer design, and complementary 
qRT‑PCR
Total RNA isolated from one passage of NEB1 and 
KEB7 cells (each cell line in technical triplicates) was 
treated with DNase I (Sigma-Aldrich, Taufkirchen, Ger-
many) and then reverse transcribed into cDNA using 
an iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories 
Inc., Hercules, CA USA) according to the manufacturer’s 
instructions. The resultant cDNAs served as template for 
complementary quantitative real-time PCR (qRT-PCR) 
in a 96-well plate format using GoTaq®qPCR Master 
Mix (Promega Corporation, Madison, WI, USA) and a 
CFX96™ instrument (Bio-Rad Laboratories). Using Batch 
Entrez (http://www.ncbi.nlm.nih.gov/sites/batchentrez) 
and WIBR UTR extractor (http://jura.wi.mit.edu/bioc/
tools/utrs/), we extracted the coding sequences (high-
lighted within the downloaded mRNAs) of the 79 most 
promising up-regulated and the 79 most promising 
down-regulated genes uncovered in the microarray anal-
ysis to automatically design oligonucleotides with simi-
lar properties (uniform GC content, comparable melting 
temperature, optimal length and similar product size; 
BATCH Primer 3 program, http://probes.pw.usda.gov/
cgi-bin/batchprimer3/batchprimer3.cgi). Forward and 
reverse primer stocks (100 pmol/µl, see Additional file 2: 
Table S2) were purchased in 96-well format from Life 
Technologies GmbH (Karlsruhe, Germany). Differential 
expression of selected candidate genes was investigated 
by performing three independent PCR-runs (biological 
and technical replicates) in an in-house developed and 
established 96-well qRT-PCR array format. Seven consti-
tutively expressed housekeeping genes (ACTB, ANXA1, 
B2 M, GAPDH, HPRT1, RPL13A, and TUBB) served as 
internal controls for data normalization as well as deter-
mination of experimental variance. Fold inductions and 
statistical significance were assessed via RealTimeStat-
Miner® from Integromics® that calculates the relative 
quantity (RQ) and log2-fold change using ΔΔCt (cycle 
threshold) and efficiency correction [18]. A parametric 
LIMMA moderate t-test [17] and a Benjamini–Hoch-
berg false discovery rate (FDR) p-value correction [19], 
included as standard default parameters of the software 
(log2-fold change of +1/−1, p-value <0.05), were applied 
in the data analysis. The meaning of an FDR-adjusted 
p-value is that, if all genes with a p-value below a thresh-
old of 0.05 are picked as differentially expressed, then the 
expected proportion of false discoveries in the selected 
group is controlled to be less than the threshold value, in 
this case 5 %.
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KEB7/NEB1 total protein lysates and Western blotting
For preparation of KEB7 versus NEB1 protein lysates 
(using three 75-cm2 flasks per cell line), the culture 
medium was removed, the cells were rinsed twice with 
sterile PBS, and then lysed in RIPA buffer (Radio-Immu-
noprecipitation Assay buffer; 150  mM NaCl, 1  % IGE-
PAL® CA-630, 0.5  % deoxycholate, 0.1  % SDS, 50  mM 
Tris–HCl, pH 8.0, Sigma-Aldrich) supplemented with 
1× Protease Inhibitor Cocktail (GE Healthcare, USA) for 
10 min at RT (room temperature) and a further 20 min at 
−80 °C. Cells were detached with a cell scraper, and the 
resultant total protein lysates transferred to 1.5-ml tubes 
and centrifuged at maximum speed for 15  s to remove 
cellular debris. Protein in the supernatants was photo-
metrically quantified by a standard Bradford assay (Bio-
Rad, Hercules, CA, USA), and the samples were frozen 
at −80  °C for long-term storage. 10 µg of protein lysate 
per slot were subjected to SDS-PAGE (sodium dode-
cyl sulfate polyacrylamide gel electrophoresis) and then 
transferred onto Amersham™ Hybond™ ECL nitrocel-
lulose membranes (GE Healthcare). After blocking of 
the membrane in 3 % nonfat milk in Tris-buffered saline 
(TBS, pH 8.0, Sigma-Aldrich) containing 0.05 % Tween-
20 for 1  h at RT, target-specific primary antibodies 
diluted 1:1000 in TBS with 0.05 % Tween-20 were added 
overnight at 4 °C with gentle agitation (Wnt-5a antibody, 
sc-365370, mouse monoclonal, Santa Cruz Biotechnol-
ogy, Inc.; Cytokeratin 19 antibody, 11-120-C020, mouse 
monoclonal, EXBIO Praha a.s.; SOX2 antibody, D1951-
1NB-1-1R1M1M3/1C16_110120, mouse monoclonal, 
ABMART; GAPDH antibody, TA302944-100, goat poly-
clonal, OriGene; antibodies were pre-tested for adequate 
performance in different human cell lysates; data not 
shown). The next day the membranes were incubated in 
horseradish-peroxidase (HRP)-labeled secondary anti-
bodies (1:10,000, polyclonal rabbit anti-mouse IgG/HRP, 
polyclonal rabbit anti-goat IgG/HRP, Dako Denmark 
A/S, Glostrup, Denmark) for 1 h at RT. Blots were devel-
oped using Immobilon™ Western Chemiluminescent 
HRP Substrate (Merck/Millipore, Darmstadt, Germany) 
and signals detected with a ChemiDoc XRS system (Bio-
Rad Laboratories). Band intensities were densitometri-
cally quantified by using the image-processing program 
ImageJ (http://rsb.info.nih.gov/ij/).
Results
Global transcriptional profiling uncovers 207 differentially 
expressed genes in the EBS‑DM cell line KEB7
Transcriptional profiling using the Affymetrix Human 
Gene 1.0 ST gene chip platform offers coverage of nearly 
the entire transcriptome, defined by 28,869 annotated 
open reading frames/genes. We applied this platform to 
study the expression pattern of genes influenced by the 
cytoskeletal collapse caused by the R125P mutation in 
KRT14 in KEB7 cells. Table 1 summarizes the results of 
our microarray profiling (four technical replicates each) 
using a pool of different passages (biological replicates) 
of KEB7 cells relative to NEB1 wild-type control cells. A 
LIMMA statistical test comparing mutant versus wild-
type cells identified 106 up-regulated and 101 down-reg-
ulated genes with significantly altered expression levels 
(log2-fold change ≥+1 and ≤−1, adjusted p-value <0.05) 
out of 382 differentially expressed genes (failed at log2-
fold change and p-value set).
Bioinformatic enrichment and clustering suggest 
previously undescribed pathways and functions are 
affected in EBS‑DM
We next assigned cellular themes to the differentially 
expressed genes by using IBD software. Functional 
annotation clustering allowed us to group highly related 
annotation terms into enriched functional categories, 
as shown in Table  2. The enrichment p-values of each 
GO term are presented as the ordered p-value of a one-
sided hypergeometric test. Significance of enrichment 
is indicated by a p-value of  <0.05. Apart from already 
well-known clusters such as the regulation of epithe-
lial cell proliferation [20], cell adhesion and response to 
stress [12, 13], response to retinoic acid and UV [21–23], 
immune response [11] or fatty acid metabolism [14], our 
analysis also identified previously undescribed functional 
classes potentially implicated in EBS-DM. The latter 
include genes involved in morphogenesis, and genes that 
regulate BMP- and canonical Wnt-signaling. In addition, 
two enrichment clusters associated with protein tyros-
ine phosphatases and symporter activities, and one fur-
ther cellular component cluster linked to neurofilaments, 
were uncovered.
A complementary qRT‑PCR array approach confirms 
differential regulation of the majority of selected 
candidates
Typically in microarray investigations, just a few ran-
domly selected candidates are re-analyzed by qRT-PCR 
analysis for confirmation of the first hits, but this can 
lead to a significant number of undetected false positives. 
In the present study we used an array-based qRT-PCR 
analysis to investigate 158 of the 207 (76  %) microar-
ray hits. To reduce the number of transcripts to be able 
to fit our in-house 96-well qRT-PCR array arrangement, 
we examined 79 randomly selected up-regulated and 79 
down-regulated genes (plus controls) in three independ-
ent PCR runs (biological and technical replicates). Fur-
thermore, we based our fold-change cut-off values on 
the average of seven housekeeping genes (rather than on 
two, as has been customary in the literature [24, 25], so 
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Table 1 Genes regulated in the EBS-DM model keratinocyte cell line KEB7 identified by microarray analysis
Microarray candidate genes  
(accession number)






KRT19 (NM_002276) Significant down-regulated −5.74 −1633.0 Significant
MIR492 (NR_030171) Significant down-regulated −4.46 n.d. n.d.
KYNU (NM_003937) Significant down-regulated −4.20 −276.6 Significant
H19, MIR675 (NR_030533) Significant down-regulated −4.12 n.d. n.d.
EYA4 (NM_004100) Significant down-regulated −4.03 n.d. n.d.
PDZK1 (NM_002614) Significant down-regulated −3.86 −8.0 Significant
TMPRSS15 (NM_002772) Significant down-regulated −3.85 n.d. n.d.
OLFM4 (NM_006418) Significant down-regulated −3.73 −8.4 Significant
SLC38A4 (NM_018018) Significant down-regulated −3.67 −12.3 Significant
BST2 (NM_004335) Significant down-regulated −3.53 −137.3 Significant
ITGBL1 (NM_004791) Significant down-regulated −2.99 n.d. n.d.
EDIL3 (NM_005711) Significant down-regulated −2.91 n.d. n.d.
PPARGC1A (NM_013261) Significant down-regulated −2.79 −964.3 Significant
GALNT5 (NM_014568) Significant down-regulated −2.73 −78.3 Significant
CDR1 (NM_004065) Significant down-regulated −2.71 n.d. n.d.
FKBP10 (NM_021939) Significant down-regulated −2.63 −26.8 Significant
GIPC2 (NM_017655) Significant down-regulated −2.55 −71.4 Significant
AMOT (NM_001113490) Significant down-regulated −2.53 −3015.8 Significant
ZNF114 (NM_153608) Significant down-regulated −2.52 −10.2 Significant
CLEC2B (NM_005127) Significant down-regulated −2.50 −182.1 Significant
FAM198B (NM_001031700) Significant down-regulated −2.50 −14.0 Significant
SLC2A3 (NM_006931) Significant down-regulated −2.48 −88.7 Significant
CAPNS2 (NM_032330) Significant down-regulated −2.43 −9.0 Significant
TBX18 (NM_001080508) Significant down-regulated −2.43 −89.4 Significant
LRCH2 (NM_020871) Significant down-regulated −2.36 −44.2 Significant
NEFM (NM_005382) Significant down-regulated −2.34 −7.7 Significant
CPT1C (NM_001136052) Significant down-regulated −2.32 −13.4 Significant
ZNF43 (NM_001256648) Significant down-regulated −2.22 −9.7 Significant
LY75, LY75-CD302 (NM_002349) Significant down-regulated −2.17 −8.6 Significant
LOC100129717, NEFL (NM_006158) Significant down-regulated −2.16 n.d. n.d.
GLDC (NM_000170) Significant down-regulated −2.14 −307.6 Significant
TMTC1 (NM_001193451) Significant down-regulated −2.13 −6.7 Significant
SLCO1B3 (NM_019844) Significant down-regulated −2.10 −988.0 Significant
SMOC2 (NM_022138) Significant down-regulated −2.09 n.d. n.d.
SLC6A14 (NM_007231) Significant down-regulated −2.02 −4.9 Significant
SLC24A3 (NM_020689) Significant down-regulated −1.97 −53.0 Significant
EPSTI1 (NM_001002264) Significant down-regulated −1.96 −10.8 Significant
SATB2 (NM_001172509) Significant down-regulated −1.94 −224.2 Significant
HSD17B2 (NM_002153) Significant down-regulated −1.89 −59.8 Significant
GHR (NM_000163) Significant down-regulated −1.87 n.d. n.d.
TFPI2 (NM_006528) Significant down-regulated −1.86 n.d. n.d.
AKR1B10 (NM_020299) Significant down-regulated −1.86 −3.8 Significant
ARHGAP28 (NM_001010000) Significant down-regulated −1.81 n.d. n.d.
LOC100506941, NNMT (NM_006169) Significant down-regulated −1.81 n.d. n.d.
GPC3 (NM_001164617) Significant down-regulated −1.81 −427.1 Significant
IFITM3 (JQ610621) Significant down-regulated −1.80 −8.7 Significant
HOXD10 (NM_002148) Significant down-regulated −1.79 −100.8 Significant
MSX2 (NM_002449) Significant down-regulated −1.77 −9.5 Significant
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Table 1 continued
Microarray candidate genes  
(accession number)






IL17RB (NM_018725) Significant down-regulated −1.75 −9.1 Significant
BLMH (NM_000386) Significant down-regulated −1.74 −4.8 Significant
SOX2 (NM_003106) Significant down-regulated −1.72 n.d. n.d.
HIST1H Significant down-regulated −1.70 n.d. n.d.
SLC9A2 (NM_003048) Significant down-regulated −1.69 −17.0 Significant
CPNE1, RBM12 (NM_006047) Significant down-regulated −1.68 −14.9 Significant
WDR17 (NM_170710) Significant down-regulated −1.60 −11.2 Significant
RB1 (NM_000321) Significant down-regulated −1.58 −4.4 Significant
DPYD (NM_000110) Significant down-regulated −1.57 −3.7 Significant
PCCA (NM_000282) Significant down-regulated −1.56 n.d. n.d.
ZNF570 (NM_001300993) Significant down-regulated −1.51 n.d. n.d.
PRTFDC1 (NM_020200) Significant down-regulated −1.49 n.d. n.d.
GLRX (NM_002064) Significant down-regulated −1.47 −2.8 Significant
SLC7A2 (NM_003046) Significant down-regulated −1.45 −1.5 Non-significant
PPP1R16B (NM_015568) Significant down-regulated −1.44 −8.0 Significant
IKZF3 (NM_012481) Significant down-regulated −1.41 −1.8 Non-significant
GTF2H2D Significant down-regulated −1.40 −4.2 Significant
CDK14 (NM_001287135) Significant down-regulated −1.40 n.d. n.d.
REPS2 (NM_004726) Significant down-regulated −1.38 −4.5 Significant
MEST (NM_002402) Significant down-regulated −1.38 n.d. n.d.
CYP4V2 (NM_207352) Significant down-regulated −1.35 −4.7 Significant
GPR143 (NM_000273) Significant down-regulated −1.35 −2.1 Significant
GTF2H2 (NM_001515) Significant down-regulated −1.35 −4.0 Significant
CYP7B1 (NM_004820) Significant down-regulated −1.32 n.d. n.d.
BCL11A (NM_022893) Significant down-regulated −1.31 −3.6 Significant
MERTK (NM_006343) Significant down-regulated −1.30 −5.0 Significant
PRDM5 (NM_018699) Significant down-regulated −1.28 −6.1 Significant
ACOXL (NM_001142807) Significant down-regulated −1.28 −11.6 Significant
AHCY (NM_000687) Significant down-regulated −1.27 −2.0 Significant
ARMCX2 (NM_177949) Significant down-regulated −1.24 −22.5 Significant
PAX6 (NM_000280) Significant down-regulated −1.23 −14.2 Significant
HOXD11 (NM_021192) Significant down-regulated −1.23 −49.4 Significant
SMARCA1 (NM_003069) Significant down-regulated −1.22 −4.1 Significant
IFI44L (NM_006820) Significant down-regulated −1.22 −57.0 Significant
GALNTL4 Significant down-regulated −1.20 n.d. n.d.
PITRM1 (NM_001242307) Significant down-regulated −1.19 −2.3 Significant
CRIP2 (NM_001312) Significant down-regulated −1.18 n.d. n.d.
NAP1L5 (NM_153757) Significant down-regulated −1.15 −20.7 Significant
IPO7 (NM_006391) Significant down-regulated −1.15 n.d. n.d.
SAAL1 (NM_138421) Significant down-regulated −1.13 n.d. n.d.
KRTCAP3 (NM_001168364) Significant down-regulated −1.12 n.d. n.d.
FAM159A (NM_001042693) Significant down-regulated −1.11 n.d. n.d.
EYA1 (NM_172060) Significant down-regulated −1.09 n.d. n.d.
PIGU (NM_080476) Significant down-regulated −1.09 −3.2 Significant
CDC25B (NM_021873) Significant down-regulated −1.09 n.d. n.d.
NKX2-6 (NM_001136271) Significant down-regulated −1.07 n.d. n.d.
HTATIP2 (NM_001098520) Significant down-regulated −1.05 n.d. n.d.
ILK (NM_004517) Significant down-regulated −1.05 n.d. n.d.
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Table 1 continued
Microarray candidate genes  
(accession number)






ACSF2 (NM_001288968) Significant down-regulated −1.04 n.d. n.d.
PDZD2 (NM_178140) Significant down-regulated −1.03 n.d. n.d.
CENPH (NM_022909) Significant down-regulated −1.03 n.d. n.d.
TOX (NM_014729) Significant down-regulated −1.02 n.d. n.d.
VSTM2L (NM_080607) Significant down-regulated −1.01 n.d. n.d.
SYT17 (NM_016524) Significant down-regulated −1.01 n.d. n.d.
Microarray candidate genes  
(accession number)






TDRD12 (NM_001110822) Significant up-regulated 3.98 618.1 Significant
NEFH (NM_021076) Significant up-regulated 3.45 1174.9 Significant
NLRP2 (NM_017852) Significant up-regulated 3.39 154.3 Significant
TSPYL5 (NM_033512) Significant up-regulated 3.20 n.d. n.d.
KLK5 (NM_012427) Significant up-regulated 3.18 62.8 Significant
ENPP1 (NM_006208) Significant up-regulated 3.09 6.1 Significant
GJB6 (NM_001110219) Significant up-regulated 2.98 24.4 Significant
ZFP42 (NM_174900) Significant up-regulated 2.84 313.7 Significant
RNF212 (NM_001131034) Significant up-regulated 2.59 n.d. n.d.
DDX43 (NM_018665) Significant up-regulated 2.51 n.d. n.d.
DKK1 (NM_012242) Significant up-regulated 2.40 45.3 Significant
CYYR1 (NM_052954) Significant up-regulated 2.36 19.6 Significant
C10orf99 (NM_207373) Significant up-regulated 2.33 10.6 Significant
SYCP2 (NM_014258) Significant up-regulated 2.23 10.2 Significant
ZNF136 (NM_003437) Significant up-regulated 2.17 n.d. n.d.
CCDC144A (NM_014695) Significant up-regulated 2.11 n.d. n.d.
PRICKLE1 (NM_153026) Significant up-regulated 2.08 52.4 Significant
SLC44A5 (NM_152697) Significant up-regulated 2.06 100.5 Significant
PLA2G7 (NM_005084) Significant up-regulated 2.05 18.6 Significant
CCDC144A, CCDC144B, CCDC144C Significant up-regulated 2.01 n.d. n.d.
MOXD1 (NM_015529) Significant up-regulated 1.97 15.9 Significant
ZNF700 (NM_144566) Significant up-regulated 1.96 n.d. n.d.
WNT5A (NM_003392) Significant up-regulated 1.94 6.9 Significant
WISP3 (CCN6) (NM_003880) Significant up-regulated 1.92 103.8 Significant
ARHGEF9 (NM_015185) Significant up-regulated 1.88 25.0 Significant
HSD17B11 (NM_016245) Significant up-regulated 1.87 3.1 Significant
BGN (NM_001711) Significant up-regulated 1.87 1.8 Non-significant
ADAMTSL3 (NM_207517) Significant up-regulated 1.84 26.4 Significant
FAM102B (NM_001010883) Significant up-regulated 1.78 2.5 Significant
SGMS1 (NM_147156) Significant up-regulated 1.76 2.9 Significant
ARHGAP29 (NM_004815) Significant up-regulated 1.75 4.1 Significant
H2AFY2 (NM_018649) Significant up-regulated 1.74 1.8 Non-significant
SLC15A2 (NM_021082) Significant up-regulated 1.73 4.6 Significant
ROBO1 (NM_002941) Significant up-regulated 1.73 5.6 Significant
ERCC6, PGBD3 (NM_000124) Significant up-regulated 1.68 6.0 Significant
NREP (NM_004772) Significant up-regulated 1.67 3.0 Significant
KIAA1324L (NM_001142749) Significant up-regulated 1.62 149.8 Significant
SNORD116-21 (NR_003335) Significant up-regulated 1.62 n.d. n.d.
HOXA9 (NM_152739) Significant up-regulated 1.59 1.3 Non-significant
ROR1 (NM_005012) Significant up-regulated 1.59 9.5 Significant
RPS23 (NM_001025) Significant up-regulated 1.58 n.d. n.d.
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Table 1 continued
Microarray candidate genes  
(accession number)






MAN1A1 (NM_005907) Significant up-regulated 1.55 1.0 Non-significant
STOX1 (NM_152709) Significant up-regulated 1.54 −1.1 Non-significant
RPL10, SNORA70 (NM_006013) Significant up-regulated 1.53 −1.1 Non-significant
CCDC144C Significant up-regulated 1.52 n.d. n.d.
ZFAND4 (NM_174890) Significant up-regulated 1.50 2.5 Significant
NOX5, SPESP1 (NM_024505) Significant up-regulated 1.50 n.d. n.d.
EVC2 (NM_147127) Significant up-regulated 1.46 n.d. n.d.
SELENBP1 (NM_003944) Significant up-regulated 1.45 64.8 Significant
ZNF334 (NM_018102) Significant up-regulated 1.43 15.6 Significant
PTPN20C (NM_001042357) Significant up-regulated 1.43 n.d. n.d.
IRX4 (NM_001278632) Significant up-regulated 1.41 90.4 Significant
PTPN20A (NM_001042357) Significant up-regulated 1.41 29.5 Significant
PTPN20B (NM_001042357) Significant up-regulated 1.40 n.d. n.d.
PNMAL1 (NM_018215) Significant up-regulated 1.40 2.9 Significant
NID1 (NM_002508) Significant up-regulated 1.38 1.8 Non-significant
ZNF32 (NM_006973) Significant up-regulated 1.37 3.5 Significant
ASAH2 (NM_019893) Significant up-regulated 1.37 n.d. n.d.
FLJ20444, LOC554249 Significant up-regulated 1.36 n.d. n.d.
TP53INP1 (NM_033285) Significant up-regulated 1.35 1.6 Non-significant
SLC16A4 (NM_004696) Significant up-regulated 1.34 16.4 Significant
FRG1B (NR_003579) Significant up-regulated 1.32 n.d. n.d.
AHI1 (NM_001134831) Significant up-regulated 1.32 3.7 Significant
MSLN (NM_005823) Significant up-regulated 1.30 n.d. n.d.
ELAVL2 (NM_004432) Significant up-regulated 1.29 4.3 Significant
SLC16A9 (NM_194298) Significant up-regulated 1.28 2.4 Significant
FAM25A, FAM25B, FAM25C, FAM25G 
(NM_001146157)
Significant up-regulated 1.28 2.5 Significant
MAPK8 (NM_002750) Significant up-regulated 1.28 2.2 Significant
CDC14B (NM_003671) Significant up-regulated 1.26 3.0 Significant
GABPB2 (NM_144618) Significant up-regulated 1.26 2.3 Significant
DENND1B (NM_144977) Significant up-regulated 1.25 n.d. n.d.
TCHH (NM_007113) Significant up-regulated 1.23 28.0 Significant
LMF1 (NM_022773) Significant up-regulated 1.22 5.1 Significant
CSTF2T (NM_015235) Significant up-regulated 1.22 2.2 Significant
IFFO2 (NM_001136265) Significant up-regulated 1.21 n.d. n.d.
SGK1 (NM_005627) Significant up-regulated 1.19 4.2 Significant
HOXC10 (NM_017409) Significant up-regulated 1.19 2.2 Significant
STRBP (NM_018387) Significant up-regulated 1.18 n.d. n.d.
UAP1 (NM_003115) Significant up-regulated 1.18 2.3 Significant
POPDC2 (NM_022135) Significant up-regulated 1.18 3.9 Significant
DSEL (NM_032160) Significant up-regulated 1.17 −1.2 Non-significant
AOX1 (NM_001159) Significant up-regulated 1.16 1.4 Non-significant
ZNF502 (NM_033210) Significant up-regulated 1.16 500.9 Significant
LRP12 (NM_013437) Significant up-regulated 1.15 n.d. n.d.
ADHFE1 (NM_144650) Significant up-regulated 1.12 1.8 Non-significant
FAM21D Significant up-regulated 1.11 n.d. n.d.
SNORD64 (NR_001294) Significant up-regulated 1.10 n.d. n.d.
FAM21A, FAM21B, FAM21C Significant up-regulated 1.09 n.d. n.d.
EFEMP1 (NM_001039348) Significant up-regulated 1.09 n.d. n.d.
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Microarray candidate genes  
(accession number)






KGFLP1, KGFLP2 Significant up-regulated 1.08 n.d. n.d.
ANKRD2 (NM_020349) Significant up-regulated 1.07 −1.4 Non-significant
PIK3R3 (NM_003629) Significant up-regulated 1.07 n.d. n.d.
HS3ST3B1 (NM_006041) Significant up-regulated 1.07 1.2 Non-significant
PTPN20A, PTPN20B (NM_001042357) Significant up-regulated 1.07 n.d. n.d.
FAM21A, FAM21B, FAM21C Significant up-regulated 1.07 n.d. n.d.
APBB2 (NM_004307) Significant up-regulated 1.06 n.d. n.d.
DUOX1 (NM_017434) Significant up-regulated 1.06 n.d. n.d.
ZNF627 (NM_145295) Significant up-regulated 1.06 n.d. n.d.
MCOLN2 (NM_153259) Significant up-regulated 1.06 n.d. n.d.
APOB (NM_000384) Significant up-regulated 1.04 n.d. n.d.
AJAP1 (NM_018836) Significant up-regulated 1.04 n.d. n.d.
BNC2 (NM_017637) Significant up-regulated 1.03 n.d. n.d.
LOC100652860, LOC100653093, TTC6 Significant up-regulated 1.03 n.d. n.d.
FKTN (NM_001079802) Significant up-regulated 1.03 n.d. n.d.
TMEM204 (NM_024600) Significant up-regulated 1.02 n.d. n.d.
BMS1P1, BMS1P5 (NR_003611) Significant up-regulated 1.00 n.d. n.d.
106 up-regulated and 101 down-regulated genes with significantly altered expression levels (log2-fold-change >+1 and <−1 and adjusted p-value <0.05) in the 
mutant cell line KEB7 compared to wild-type control NEB1 keratinocytes. qRT-PCR analysis of the most promising 79 up-regulated and 79 down-regulated genes was 
also carried out (a fold-change >±2 is statistically significant, p < 0.05)
Table 2 Gene ontology (GO) functional annotation clustering
Differentially regulated genes in EBS-DM KEB7 versus wild-type NEB1 cells were assigned GO terms and classified into clusters, which were further classified as 
biological processes (1), molecular functions (2) and cellular components (3). Statistical significance of each term was calculated by a one-sided hypergeometric test; a 
cluster with an adjusted p-value <0.05 was considered significant. Per cluster, a minimum of 3 genes (up- or down-regulated) is significant, equating to nearly 10 % of 
all annotated genes per enriched term
Cluster GO# Term Annotated Significant Expected p value
(1)—16 clusters
 1 GO:0050680 Negative regulation of epithelial cell proliferation 42 5 0.4881 0.0001
 2 GO:0001658 Branching involved in ureteric bud morphogenesis 41 4 0.4765 0.0013
 3 GO:0009954 Proximal/distal pattern formation 21 3 0.2440 0.0018
 4 GO:0034341 Response to interferon-gamma 19 3 0.2208 0.0013
 5 GO:0034613 Cellular protein localization 36 4 0.4183 0.0008
 6 GO:0090103 Cochlea morphogenesis 20 3 0.2324 0.0015
 7 GO:0032526 Response to retinoic acid 51 4 0.5927 0.0029
 8 GO:0006024 Glycosaminoglycan biosynthetic process 30 3 0.3486 0.0050
 9 GO:0006635 Fatty acid beta-oxidation 28 3 0.3254 0.0041
 10 GO:0010811 Positive regulation of cell-substrate adhesion 29 3 0.3370 0.0045
 11 GO:0030513 Positive regulation of BMP signaling pathway 31 3 0.3602 0.0055
 13 GO:0048704 Embryonic skeletal system morphogenesis 38 3 0.4416 0.0097
 14 GO:0090090 Negative regulation of canonical Wnt receptor signaling pathway 71 4 0.8251 0.0093
 15 GO:0030326 Embryonic limb morphogenesis 39 3 0.4532 0.0104
 16 GO:0009411 Response to UV 41 3 0.4765 0.0119
(2)—2 clusters
 17 GO:0004725 Protein tyrosine phosphatase activity 84 5 1.0065 0.0033
 18 GO:0015293 Symporter activity 43 4 0.5152 0.0017
(3)—1 clusterr
 19 GO:0005883 Neurofilament 9 3 0.1026 0.0001
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at to improve the reliability of the data obtained). Out of 
the 158 genes analyzed, significant (p-value  <0.05) dif-
ferences in expression (fold change set ≥+2 for up-reg-
ulated and ≤−2 for down-regulated genes) of 121 genes 
(~76.58  %) was confirmed, as highlighted in Table  1. 
Eleven genes (~6.96 %) turned out not to be significantly 
modulated, and 26 genes (~16.45  %) completely failed 
in all independent PCR runs, probably due to poorly 
designed primers; this would potentially give an underes-
timate of the number of reproducible hits.
Western blot analysis confirms differential expression 
at the protein level of 3 selected candidates
Western blot analysis using crude lysates of KEB7 and 
NEB1 cells confirmed differential regulation of some of the 
selected candidates at the protein level after normalization 
with glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), 
as shown in Fig. 2. Sex determining region Y-box 2 (SOX2, 
a log2-fold change of −1.71 by microarray analysis, no data 
by qRT-PCR) and cytokeratin 19 (KRT19, log2-fold change 
of −5.73 by microarray analysis, 1633-fold down-regulation 
by qRT-PCR) were both found to be significantly down-reg-
ulated in KEB7 cells, whereas wingless-type MMTV inte-
gration site family member 5a (WNT5a) was found to be 
significantly up-regulated (log2-fold change of 1.94 by micro-
array analysis, 6.9-fold up-regulation by qRT-PCR). Based 
on densitometric evaluation of the protein blots, SOX2 is 
25-fold down-regulated, KRT19 61.7-fold down-regulated, 
and WNT5a 123-fold up-regulated in KEB7 cells.
Discussion
Global transcriptional profiling uncovers novel 
differentially expressed genes as well as affected pathways 
in the EBS‑DM cell line KEB7
The present study employed global high-throughput 
microarray analysis together with bioinformatics-assisted 
functional clustering and enrichment to identify 207 dif-
ferentially expressed genes in the EBS-DM cell line KEB7. 
A subset of 158 genes was subjected to further investiga-
tion by qRT-PCR, of which three quarters (76.58 %) could 
be validated as being differentially regulated. Parentheti-
cally, the used human gene 1.0 ST Array from Affymetrix 
also has the ability to detect alternative mRNA isoforms. 
The mRNA source of the array transcripts arise from 
the reference sequence database (RefSeq). Each of these 
transcripts is read out by 26 different oligonucleotides 
(25mere), which are spread about the whole length of 
the transcription unit. Hence, a averaged probe set con-
sists of 26 independent measure points per transcript, 
which are summated in only one signal. Because we have 
not taken into account this feature of the array to detect 
these alternative mRNA isoforms or splice variants we 
designed for qPCR validation only primer pairs for one 
transcript variant. Therefore, the number of our repro-
ducible hits could potentially be underestimated.
In addition to verifying genes from previous stud-
ies (and thereby supporting their potential role in EBS 
pathology), a novel contribution of the present work is 
its uncovering of genes involved in the BMP-signaling 
Fig. 2 Western blot analysis for confirmation of differential expression at the protein level of 3 selected candidates—KRT19, WNT5a and SOX2. 
GAPDH occurred as normalization protein
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pathway, the canonical Wnt-receptor signaling pathway, 
and the response to retinoic acid, suggesting that dys-
regulation of these processes as well may play a role in 
disease pathology. It is well demonstrated that keratino-
cyte differentiation is closely linked to hormonal action, 
particularly to calcitriol- [26, 27] and retinoic acid-sign-
aling [21, 23]. In the present study, we identified four dif-
ferentially regulated genes in KEB7 cells having roles in 
retinoic acid signaling: three genes, HSD17B2 (hydroxys-
teroid (17-β) dehydrogenase 2), SOX2 and MEST (meso-
derm specific transcript), are down-regulated, and DKK1 
(dickkopf Wnt signaling pathway inhibitor 1) is up-regu-
lated. These potential disturbances to retinoic acid sign-
aling may at least partially account for the observations 
by Wagner et al. [15] of aberrant differentiation processes 
in KEB7 cells. Generally, retinoids are considered to play 
a role in normalization of keratinocyte differentiation by 
down-regulating desmosomal proteins, exerting anti-pro-
liferative effects, and regulating lipid-synthesis, growth 
factors, and cytokines [22, 23, 28, 29]. An interesting 
point in this regard is the ability of retinoic acid to act as 
an antagonist of Jun N-terminal kinase (JNK)-signaling, 
mediated by activating protein 1 (AP1) [30], since JNK/
mitogen activated protein kinase (MAPK) signal trans-
duction has previously been shown to be dysregulated in 
EBS-DM model keratinocytes [9, 31, 32]. Furthermore, 
we recently advanced a positive feedback model, sug-
gesting that mutant KRT14 leads to an increase in AP1-
dependent expression of KRT14, which in turn amplifies 
the level of aberrant JNK stress-signaling [33]. Con-
cerning the canonical Wnt-receptor signaling pathway, 
enrichment clustering applied in our present study iden-
tified four significantly dysregulated genes: GPC3 (glypi-
can3) and SOX2 are both down-regulated, and WNT5a 
and PRICKLE1 (prickle homolog 1) are up-regulated. 
Interestingly, WNT5a is one of the so-called non-canon-
ical Wnt ligands. During normal development, WNT5a 
is secreted and directs the migration of target cells along 
concentration gradients. However, deregulated WNT5a 
signaling facilitates invasion by multiple tumor types 
into contiguous tissues. EB per se is often associated with 
carcinoma development, mostly in EB dystrophicans 
(DEB) and junctionalis (JEB) [34–36], but rare cases of 
carcinoma in EBS have also been described [36]. To date, 
the roles of WNT5a in cutaneous squamous cell carci-
noma (SCC) and basal cell carcinoma (BCC) as well as 
the effect of WNT5a on keratinocyte migration have not 
been fully investigated, although Pourreyron et  al. [37] 
recently demonstrated up-regulation of WNT5a in SCC/
BCC and its localization to the leading edge of tumors as 
well as in tumor-associated fibroblasts. Regarding BMP 
signaling, enrichment clustering showed positive regula-
tion of this pathway in EBS by highlighting three genes, 
GPC3, MSX2 (Msh homeobox 2) and ILK (Integrin-
linked kinase), as being significantly down-regulated. 
BMPs are secreted signaling polypeptides belonging to 
the transforming growth factor-β (TGF-β) superfamily 
that act as important multifactor players in the develop-
ment of vertebrate skin (and appendages). BMPs thereby 
not only regulate hair follicle (HF) morphogenesis and 
keratinocyte differentiation in both the HF and epider-
mis, but are, along with other interacting growth factor 
family members, also involved in normal postnatal tissue 
remodeling and homeostasis [38, 39]. Furthermore, BMP 
signaling acts as a potent tumor suppressor in the skin, 
inhibiting mainly epidermal- and HF-derived tumor for-
mation [38, 40]. Consequently, dysregulation of this path-
way can lead to abnormal skin development and tumor 
formation. Progress in this research area could be inter-
esting to get a better knowledge of the disease pathology.
KRT19—a novel biomarker in EBS‑DM?
A further example from our list of dysregulated genes is 
the smallest known acidic keratin, KRT19 (significantly 
down-regulated in our microarray analysis, indepen-
dently confirmed by both qRT-PCR and western blot-
ting). In our previous study, in which we applied a similar 
whole-transcriptome microarray methodology to calci-
triol-stimulated human primary keratinocytes, we [41] 
found a significantly increased expression level of KRT19 
after treatment with the indicated secosteroid. Hence, 
irrespective of the exact role of KRT19 in the disease 
mechanism, it could constitute another useful biomarker 
in EBS.
Conclusions
In summary, our study employed global high-throughput 
microarray analysis plus bioinformatics-assisted func-
tional clustering and enrichment to uncover 207 differen-
tially expressed genes in the EBS-DM cell line. Thereof, 
158 genes were subjected to further investigation by a 
complementary qRT-PCR analysis, of which 76.58  % 
could be validated as being differentially regulated. We 
here present a pool of novel candidate genes and poten-
tial affected pathways, which may play a role in the dis-
ease pathology.
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